About the Company
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stagepreclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.
Employees
10
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MNPR News
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on ...
Monopar Therapeutics (MNPR) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer ...
Monopar shares rise on positive tumor imaging data
WILMETTE, Ill. - Monopar Therapeutics Inc . (NASDAQ:MNPR), a biopharmaceutical company engaged in the development of cancer treatments, today announced new preclinical imaging data showing ...
Monopar Therapeutics Inc.: Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer ...
Monopar Therapeutics Inc.: Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients ...
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...
Monopar Therapeutics Inc (MNPR)
Monopar Therapeutics Inc . (Nasdaq: NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced... Monopar Therapeutics ...
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced positive preclinical imaging ...
Loading the latest forecasts...